Detection of SARS-CoV-2 Antibodies in Oral Fluid Using a Magnetic Particle-Based Chemiluminescence Immunoassay — Beijing Municipality, China, 2021

Naiying Mao(Centers for Disease Control and Prevention), Wenbo Xu(Shenyang Institute of Automation), Zhen Zhu(Center for Disease Control), Fang Huang(National Institute for Parasitic Diseases), Yu Xiali(Beijing Center for Disease Prevention and Control), Qi Huang(Shanghai University of Traditional Chinese Medicine), Hui Xie(Jiangsu Cancer Hospital), Jianping Dong, Mei Dong(Khazar University), Jingyi Sun(Beijing Haidian Hospital)
China CDC Weekly
January 1, 2022
10.46234/ccdcw2022.185
Cited by 2

Related Papers

A Novel Coronavirus from Patients with Pneumonia in China, 2019
|New England Journal of Medicine|2020|30.5k
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
|The Lancet|2020|12.6k
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
|Nature|2020|1.2k
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
|Cell|2020|802
An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of Hand Foot and Mouth Disease in Fuyang city of China
|Virology Journal|2010|473